{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:42:30Z","timestamp":1757619750668,"version":"3.44.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Commission of Sichuan Province Medical Science and Technology Program","award":["24WSXT074"],"award-info":[{"award-number":["24WSXT074"]}]},{"name":"National Anti-Tumor Drug Surveillance System of National Cancer Center","award":["DSS-YSF-202311"],"award-info":[{"award-number":["DSS-YSF-202311"]}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2022-01-11"],"award-info":[{"award-number":["320.6750.2022-01-11"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12858-y","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T14:26:54Z","timestamp":1753453614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study"],"prefix":"10.1038","volume":"15","author":[{"given":"Xiaochun","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanjie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"12858_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"12858_CR2","unstructured":"National Comprehensive Cancer Network. Hepatocellular Carcinoma. Version 2. (2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hcc.pdf (2023)."},{"key":"12858_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo, M. et al. Management of hepatocellular carcinoma in japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 10, 181\u2013223 (2021).","journal-title":"Liver Cancer"},{"key":"12858_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.amjsurg.2006.11.025","volume":"194","author":"S Garrean","year":"2007","unstructured":"Garrean, S., Hering, J., Helton, W. S. & Espat, N. J. A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors. Am. J. Surg. 194, 79\u201388 (2007).","journal-title":"Am. J. Surg."},{"key":"12858_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.hpb.2021.09.016","volume":"24","author":"C Serra","year":"2022","unstructured":"Serra, C. et al. Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma: a textbook outcome analysis. HPB 24, 664\u2013671 (2022).","journal-title":"HPB"},{"key":"12858_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4174\/astr.2014.87.2.72","volume":"87","author":"EK Park","year":"2014","unstructured":"Park, E. K. et al. A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Ann. Surg. Treat. Res. 87, 72\u201380 (2014).","journal-title":"Ann. Surg. Treat. Res."},{"key":"12858_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jamcollsurg.2008.01.020","volume":"207","author":"VWT Lam","year":"2008","unstructured":"Lam, V. W. T. et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J. Am. Coll. Surg. 207, 20\u201329 (2008).","journal-title":"J. Am. Coll. Surg."},{"key":"12858_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000507370","volume":"9","author":"M Kudo","year":"2020","unstructured":"Kudo, M. et al. A changing paradigm for the treatment of Intermediate-Stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements. Liver Cancer. 9, 245\u2013260 (2020).","journal-title":"Liver Cancer"},{"key":"12858_CR9","unstructured":"Peng, Z. W. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial. J Clin Oncol. 31 (2013)."},{"key":"12858_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1478-3231.2010.02221.x","volume":"30","author":"W Wang","year":"2010","unstructured":"Wang, W., Shi, J. & Xie, W. F. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 30, 741\u2013749 (2010).","journal-title":"Liver Int."},{"key":"12858_CR11","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1080\/02656736.2019.1692148","volume":"36","author":"L Wang","year":"2019","unstructured":"Wang, L. et al. The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Int. J. Hyperth. 36, 1288\u20131296 (2019).","journal-title":"Int. J. Hyperth."},{"key":"12858_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ctrv.2018.08.006","volume":"74","author":"X Chang","year":"2019","unstructured":"Chang, X., Lu, X., Guo, J. & Teng, G. J. Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treat. Rev. 74, 49\u201360 (2019).","journal-title":"Cancer Treat. Rev."},{"key":"12858_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/his.14317","volume":"79","author":"A Montasser","year":"2021","unstructured":"Montasser, A. et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology 79, 36\u201346 (2021).","journal-title":"Histopathology"},{"key":"12858_CR14","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/hep.26153","volume":"57","author":"E Mizukoshi","year":"2013","unstructured":"Mizukoshi, E. et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 57, 1448\u20131457 (2013).","journal-title":"Hepatology"},{"key":"12858_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","volume":"8","author":"HD Zhu","year":"2023","unstructured":"Zhu, H. D. et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal. Transduct. Target. Ther. 8, 58 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"12858_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall\u2019Olio","year":"2022","unstructured":"Dall\u2019Olio, F. G. et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 19, 75\u201390 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"12858_CR17","doi-asserted-by":"crossref","unstructured":"Terzi, E. et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed \u2018on demand\u2019. J Hepatol. 57, 1258\u20131267 (2012).","DOI":"10.1016\/j.jhep.2012.07.025"},{"key":"12858_CR18","doi-asserted-by":"publisher","first-page":"eaba2351","DOI":"10.1126\/sciimmunol.aba2351","volume":"5","author":"X Ficht","year":"2020","unstructured":"Ficht, X. & Iannacone, M. Immune surveillance of the liver by T cells. Sci. Immunol. 5, eaba2351 (2020).","journal-title":"Sci. Immunol."},{"issue":"Suppl 1","key":"12858_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/hep.31306","volume":"73","author":"RS Finn","year":"2021","unstructured":"Finn, R. S. & Zhu, A. X. Evolution of systemic therapy for hepatocellular carcinoma. Hepatology 73 (Suppl 1), 150\u2013157 (2021).","journal-title":"Hepatology"},{"key":"12858_CR20","doi-asserted-by":"publisher","first-page":"635243","DOI":"10.3389\/fmolb.2021.635243","volume":"8","author":"X Li","year":"2021","unstructured":"Li, X., Wang, Y., Ye, X. & Liang, P. Locoregional combined with systemic therapies for advanced hepatocellular carcinoma: an inevitable trend of rapid development. Front. Mol. Biosci. 8, 635243 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"12858_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12967-017-1124-9","volume":"15","author":"L Li","year":"2017","unstructured":"Li, L. et al. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer. J. Transl Med. 15, 23 (2017).","journal-title":"J. Transl Med."},{"key":"12858_CR22","doi-asserted-by":"publisher","first-page":"e003311","DOI":"10.1136\/jitc-2021-003311","volume":"9","author":"DJ Pinato","year":"2021","unstructured":"Pinato, D. J. et al. Trans-arterial chemoembolization as a loco-regional inducer of Immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J. Immunother Cancer. 9, e003311 (2021).","journal-title":"J. Immunother Cancer"},{"key":"12858_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","volume":"66","author":"AG Duffy","year":"2017","unstructured":"Duffy, A. G. et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J. Hepatol. 66, 545\u2013551 (2017).","journal-title":"J. Hepatol."},{"key":"12858_CR24","doi-asserted-by":"publisher","first-page":"847601","DOI":"10.3389\/fimmu.2022.847601","volume":"13","author":"F Yang","year":"2022","unstructured":"Yang, F. et al. Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: efficacy and systemic immune response. Front. Immunol. 13, 847601 (2022).","journal-title":"Front. Immunol."},{"key":"12858_CR25","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N Engl. J. Med."},{"key":"12858_CR26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus Sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 22, 977\u2013990 (2021).","journal-title":"Lancet Oncol."},{"key":"12858_CR27","doi-asserted-by":"publisher","first-page":"LBA432","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA432","volume":"42","author":"R Lencioni","year":"2024","unstructured":"Lencioni, R. et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. JCO 42, LBA432\u2013LBA432 (2024).","journal-title":"JCO"},{"key":"12858_CR28","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862\u2013873 (2022).","journal-title":"J. Hepatol."},{"key":"12858_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4103\/jcrt.JCRT_101_20","volume":"16","author":"M Meng","year":"2020","unstructured":"Meng, M. et al. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma. J. Cancer Res. Ther. 16, 327\u2013334 (2020).","journal-title":"J. Cancer Res. Ther."},{"key":"12858_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000481315","volume":"6","author":"CE Costentin","year":"2017","unstructured":"Costentin, C. E. et al. Hepatocellular carcinoma with macrovascular invasion: defining the optimal treatment strategy. Liver Cancer. 6, 360\u2013374 (2017).","journal-title":"Liver Cancer"},{"key":"12858_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/cld.129","volume":"1","author":"A Forner","year":"2012","unstructured":"Forner, A., Rodr\u00edguez-Lopez, C. & Reig, M. Natural history and staging for hepatocellular carcinoma. Clin. Liver Dis. (Hoboken). 1, 183\u2013185 (2012).","journal-title":"Clin. Liver Dis. (Hoboken)"},{"key":"12858_CR32","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3390\/cancers14102469","volume":"14","author":"A Hatzidakis","year":"2022","unstructured":"Hatzidakis, A., M\u00fcller, L., Krokidis, M. & Kloeckner, R. Local and regional therapies for hepatocellular carcinoma and future combinations. Cancers (Basel). 14, 2469 (2022).","journal-title":"Cancers (Basel)"},{"key":"12858_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin, S. et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 21, 571\u2013580 (2020).","journal-title":"Lancet Oncol."},{"key":"12858_CR34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an Open-label, dose escalation and expansion study. Clin. Cancer Res. 25, 515\u2013523 (2019).","journal-title":"Clin. Cancer Res."},{"key":"12858_CR35","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s11427-019-1753-3","volume":"64","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Sodium cantharidinate, a novel anti-pancreatic cancer agent that activates functional p53. Sci. China Life Sci. 64, 1295\u20131310 (2021).","journal-title":"Sci. China Life Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12858-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12858-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12858-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:31:40Z","timestamp":1757291500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12858-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12858"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12858-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study received ethical approval from the Institutional Review Board of Yibin First People\u2019s Hospital (Sichuan, China) and was conducted in accordance with the Declaration of Helsinki, clinical practice guidelines for liver cancer treatment, and pertinent legal and regulatory standards. All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"27123"}}